Discuva: New Antibiotics for the 21st Century

Cambridge (UK) based small molecule drug discovery company making totally novel classes of antibiotics against multi-drug-resistant bacterial pathogens

Technology (Top View)

Selecting & optimising the best drugs

SATIN
SILK

Discovery
Development

A rapid sophisticated platform of high-throughput evolution-based genetic technologies analysed using advanced machine learning and artificial intelligence

Pipeline

Programmes

Source

Disease

Internal Discuva

Different drug-resistant Gram-negative and Gram-positive infections, including Neisseria, Staph/Strep & Enterococcus

Partnered with Roche

Variety of specific hospital-acquired Gram-negative infections

Drug-resistant Gram-negative infections

Unparalleled Antibiotic Discovery

Compound general toxicity

Mechanism of compound entry & exit from the bacteria

Compound (antibiotic) resistance development in clinical context

Removal/fine-turning of compound efflux

Best Clinical Therapies

SATIN

Selecting & optimising the best drugs

Existing Antibiotics

• Proprietary

• Generic

New Chemical Entity

• Discuva’s internal series

SILK

Selecting the best drug combinations

New Long Market-life Therapies (Low Resistance)